Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Investigation of Plasma Proteins in Patients With Hereditary Haemorrhagic Telangiectasia and PAVMs

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2008 by Imperial College London.
Recruitment status was:  Recruiting
Sponsor:
Information provided by:
Imperial College London
ClinicalTrials.gov Identifier:
NCT00230672
First received: September 29, 2005
Last updated: August 12, 2008
Last verified: August 2008
  Purpose
Hereditary Haemorrhagic Telangiectasia (HHT, also known as Osler-Weber-Rendu Syndrome) is an disease that leads to the development of dilated and fragile blood vessels, including arteriovenous malformations in the lungs (PAVMs). We hypothesize that the genetically-determined abnormality in the blood vessels of HHT patients leads to alteration in the concentrations or activity of several proteins in the blood stream. We propose to take blood samples from patients at defined times in order to study changes in blood protein levels and activity

Condition
Telangiectasia, Hereditary Hemorrhagic

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Studies of Plasma Proteins Derived From Pulmonary Arteriovenous Malformation Patients

Resource links provided by NLM:


Further study details as provided by Imperial College London:

Estimated Enrollment: 70
Study Start Date: March 2005
  Eligibility

Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:Patients with hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations -

Exclusion Criteria:Unable to provide informed consent

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00230672

Locations
United Kingdom
Imperial College Hammersmith Campus
London, United Kingdom, W12 0NN
Sponsors and Collaborators
Imperial College London
Investigators
Principal Investigator: Claire Shovlin Imperial College London
  More Information

ClinicalTrials.gov Identifier: NCT00230672     History of Changes
Other Study ID Numbers: IC/CLS7 
Study First Received: September 29, 2005
Last Updated: August 12, 2008
Health Authority: United Kingdom: Research Ethics Committee

Additional relevant MeSH terms:
Arteriovenous Malformations
Vascular Malformations
Cardiovascular Abnormalities
Congenital Abnormalities
Telangiectasis
Telangiectasia, Hereditary Hemorrhagic
Vascular Diseases
Cardiovascular Diseases
Hemostatic Disorders
Hemorrhagic Disorders
Hematologic Diseases

ClinicalTrials.gov processed this record on December 06, 2016